iQSTEL, Inc. - The Calm Before The Surge (OTCQX: IQST)
October 29 2021 - 2:31PM
InvestorsHub NewsWire
October 29, 2021 -- InvestorsHub NewsWire -- via Prime Time
Profiles --
By Primetime
Editorial / Financial
IQSTEL (OTCQX:
IQST) is a diversified technology holding company that has
grown from a core telecom business into a family of tech
subsidiaries ranging from Fintech to EV.
The management team is steadily
reorganizing the subsidiary operations to seize overlapping market
opportunities where the services of one subsidiary can be sold into
the existing customer base of another subsidiary, and vice
versa.
Management’s cross selling efforts
have resulted in impressive revenue growth with the company on pace
to realize a $60 million revenue target for 2021.
Now management is working on
optimizing subsidiary redundancies to achieve operational
efficiencies that can improve profit margins.
Over a year ago when management
launched its efforts in full force to diversify from telecom into a
broader array of technologies the share price saw a meteoric climb
from $0.05 to $2.00. The PPS has since retraced and settled
in the $0.50 range plus or minus $0.10. The volatility has
settled down with the 200-day moving average climbing above the
50-day moving average late this summer.
In addition to the operational growth, management has also advanced
the company’s public reporting standards implementing an
independent board of directors, moving from the OTC Pink reporting
standard to the OTCBB and recently to the OTCQX.
Get In Now On The Nasdaq
Uplisting ROI Opportunity
The reporting standards advances
are part of the company’s stated objective to uplist to
Nasdaq. Given the steady progress the company has made thus
far in advancing its reporting standards, it’s reasonable to
presume notable progress has been made toward a Nasdaq
uplisting.
Well on track to realize $60
million in annual revenue for 2021, IQST’s market cap is still only
one times revenue at $60 million.
It would not be surprising to see
a definitive Nasdaq uplisting announcement Q1 2022 after the
company publishes its 2021 audited annual report. Along those
same lines, seeing an announcement anytime from now until the
annual report indicating the company has entered into a
relationship with a sponsoring investment bank for the Nasdaq
uplisting, would also not be surprising.
With only less than 150 million
shares outstanding, no convertible debt on the books, and $60
million in audited annual revenue anticipated to be reported for
2021, it would not be unreasonable to see IQST’s share price reach
the minimum listing requirement for a Nasdaq uplist without a
recapitalization. It could be a good time to accumulate IQST
now in the calm before a Nasdaq uplisitng surge.
Source - https://primetimeprofiles.com/iqstel-inc-the-calm-before-the-surge-otcqx-iqst/
Other stocks on the move include
NWBO,
CYDY and
ILUS.
SOURCE: Prime Time Profiles
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Dec 2024 to Jan 2025
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jan 2024 to Jan 2025